Search research articles
Contact Us
Filters
Showing results (1-10 of 57) with videos related to
Page
of 6
Sort By:
Expert Review of Clinical Pharmacology
|
December 17, 2025
Is there a link between cholesterol-lowering medications and atopic dermatitis?
John Tetteh, Zenas Z N Yiu
American Journal of Clinical Dermatology
|
March 1, 2016
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis
Zenas Z N Yiu, Richard B Warren
Expert Opinion on Investigational Drugs
|
January 3, 2017
The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis
Zenas Z N Yiu, Richard B Warren
Immunotherapy
|
February 26, 2015
Efficacy and safety of emerging immunotherapies in psoriasis
Zenas Z N Yiu, Richard B Warren
Clinical Pharmacology and Therapeutics
|
July 13, 2017
Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist
Zenas Z N Yiu, Richard B Warren
American Journal of Clinical Dermatology
|
July 22, 2021
Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say?
Marianne de Brito, Zenas Z N Yiu
The Journal of Allergy and Clinical Immunology
|
May 27, 2024
Genetically proxied IL-6 receptor inhibition is associated with increased risk of atopic dermatitis
Sizheng Steven Zhao, Zenas Z N Yiu
Expert Review of Clinical Immunology
|
November 13, 2015
Interleukin 17-A inhibition in the treatment of psoriasis
Zenas Z N Yiu, Christopher E M Griffiths
Expert Opinion on Drug Safety
|
April 2, 2020
How is safety of dermatology drugs assessed: trials, registries, and spontaneous reporting
Leila Asfour, Zenas Z N Yiu, Richard B Warren
Clinical Rheumatology
|
January 20, 2025
External validation of the accuracy of cardiovascular risk prediction tools in psoriatic disease: a UK Biobank study
David M Hughes, Zenas Z N Yiu, Sizheng Steven Zhao
Page
of 6
Search research articles
Search
Showing results (1-10 of 57) with videos related to
Sort By:
Page
of 6
Expert Review of Clinical Pharmacology
|
December 17, 2025
Is there a link between cholesterol-lowering medications and atopic dermatitis?
John Tetteh, Zenas Z N Yiu
American Journal of Clinical Dermatology
|
March 1, 2016
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis
Zenas Z N Yiu, Richard B Warren
Expert Opinion on Investigational Drugs
|
January 3, 2017
The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis
Zenas Z N Yiu, Richard B Warren
Immunotherapy
|
February 26, 2015
Efficacy and safety of emerging immunotherapies in psoriasis
Zenas Z N Yiu, Richard B Warren
Clinical Pharmacology and Therapeutics
|
July 13, 2017
Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist
Zenas Z N Yiu, Richard B Warren
American Journal of Clinical Dermatology
|
July 22, 2021
Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say?
Marianne de Brito, Zenas Z N Yiu
The Journal of Allergy and Clinical Immunology
|
May 27, 2024
Genetically proxied IL-6 receptor inhibition is associated with increased risk of atopic dermatitis
Sizheng Steven Zhao, Zenas Z N Yiu
Expert Review of Clinical Immunology
|
November 13, 2015
Interleukin 17-A inhibition in the treatment of psoriasis
Zenas Z N Yiu, Christopher E M Griffiths
Expert Opinion on Drug Safety
|
April 2, 2020
How is safety of dermatology drugs assessed: trials, registries, and spontaneous reporting
Leila Asfour, Zenas Z N Yiu, Richard B Warren
Clinical Rheumatology
|
January 20, 2025
External validation of the accuracy of cardiovascular risk prediction tools in psoriatic disease: a UK Biobank study
David M Hughes, Zenas Z N Yiu, Sizheng Steven Zhao
Page
of 6